Approved for use through U.S. Pretent and Trademark Office; U.S. DEP Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

	Application Number	10821158			
	Filing Date	2004-04-08			
First Named Inventor David		avid B. Sutton			
	Art Unit				
	Examiner Name				
	Attorney Docket Number	PRIV 0107 PUS			

	U.S.PATENTS						Remove		
Examiner Initial*			Kind Code ¹			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear			
	1	6970852	B1	2005-11-29	mX Solutions, Inc.				
	2	5477038	A	1995-12-19	Visa International				
	3	5511121	A	1996-04-23	Bell Communications Research, Inc.				
	4	6246755	B1 2001-06-		Walker Digital, LLC				
	5	6341273	B1	2002-01-22	British Telecommunications public limited company				
	6	6615189	B1	2003-09-02	Bank One, Delaware, National Association				
If you wish	h to a	dd additional U.S. Pater	t citatio	n information pl	ease click the Add button.		Add		
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where int Passages or Relevant s Appear		

	1	20020026420	A1	2002-0	2-28	Michele R. Du	.Phily		
If you wis	h to a	dd additional U.S. Publ	ished Ap	plication	citation	n information p	please click the Add t	button. Add	_
				FORE	GN PAT	ENT DOCUM	IENTS	Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4		Name of Patentee of Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T5
	1	0137228	wo		A1	2001-05-25	Hans-Peter Hackenbruch		
	2	9740616	wo		A1	1997-10-30	Gemplus S.C.A.		
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information p	lease click the Add b	utton Add	
			NON	-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Initials* Cite Initials* Cite Initials* No publisher, of yandior country where published.						Ţ5		

EXAMINER SIGNATURE

Date Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

If you wish to add additional non-patent literature document citation information please click the Add button Add

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patient Documents at were USPTO.GDV or MPEP 901.04. ² Entire office that issued the document, by the two letter code (WIPO Standard STs). ³ For Japanese patient documents, the endocation of the year of the reggo of the Emperor must precise the sensi number of the patient document. For patient programs in the contraction of the Committee of the Committee of the Patient Standard STs (Figuration sea Standard on a critication of the Committee of the Patient Standard STs (Figuration sea Standard on a critication of the Committee of the Patient Standard STs (Figuration sea Standard STs).

1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10821158
Filing Date		2004-04-08
First Named Inventor David		B. Sutton
Art Unit		
Examiner Name		
Attorney Docket Number		PRIV 0107 PUS

CERTIFICATION STATEMENT

Please see 37	7 CFR 1.	97 and	1.98 to make 1	the appropriate	selection(s):
---------------	----------	--------	----------------	-----------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

ΩR

That no item of Information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person spinifip the certification after making reasonable inquiry, no tern of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1,59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1,579(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/John E. Nemazı/	Date (YYYY-MM-DD)	2006-06-19
Name/Print	John E. Nemazi	Registration Number	30876

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issuand patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.